1002.9500 -44.50 (-4.25%)
NSE Sep 22, 2025 15:31 PM
Volume: 207.0K
High vol. this week

1002.95
-4.25%
AUM Capital
Glenmark Life Sciences (GLS) is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufactures and sells Active Pharmaceutical Ingridients (APIs) for gastro-intestinal disorders, antiinfectives and other therapeutic areas. As of March 2021, GLS had a portfolio of 120 molecules globally and sold APIs in India and exported APIs to multiple countries in Europe, North America, Latin America,...
Alivus Life Sciences Ltd.'s price crossed below 100Day SMA today
More from Alivus Life Sciences Ltd.
Recommended